Levocarb

Quick links to important sections

Levocarb

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levocarb

Property Description
Active Ingredients Levodopa (L-DOPA), Carbidopa
Form Oral tablets (standard and extended-release), Intestinal gel
Pharmacological Class Antiparkinson Agent
General Purpose Dopamine replacement for improved motor function
Type Fixed-dose combination product

What is Levocarb and What Type of Medicine is It?

Levocarb is the international non-proprietary name (INN) for a fixed-dose combination product containing the active ingredients Carbidopa and Levodopa, formally classified as an Antiparkinson Agent. This medicine is critically important in addressing the chemical deficiencies in the brain associated with certain neurodegenerative movement disorders, which are characterized by a depletion of the essential neurotransmitter dopamine. This combination therapy is clinically recognized for its efficacy in managing motor symptoms and is widely known under various trade names, including Sinemet, Rytary, and Duopa.

Composition and Formulations of Levocarb

Levocarb’s composition relies on two distinct chemical entities: Levodopa (L-DOPA), which is a synthetic preparation of a naturally occurring amino acid derivative, and Carbidopa, which is purely synthetic. This combination is available for oral administration in several dosage forms, including standard and extended-release tablets, as well as specialized liquid formulations like the intestinal gel designed for continuous enteral infusion. The availability of these different formulations, particularly the extended-release options, provides flexibility for managing motor fluctuations in patients.

General Purpose of Combining Carbidopa and Levodopa

The two ingredients are combined to achieve a critical targeted delivery of the Levodopa to the central nervous system. This pairing is essential because Levodopa is susceptible to premature breakdown by peripheral enzymes in the bloodstream before it can reach the brain. Carbidopa, a decarboxylase inhibitor, provides an effective shield by preventing this breakdown outside the brain. This synergistic action enables efficient dopamine replacement, which is the foundational goal for helping adult patients achieve better control over physical mobility and motor symptoms.

What side effects are possible with Levocarb?

The official safety documentation for the fixed-dose combination of Carbidopa and Levodopa classifies possible adverse reactions by frequency and physiological system, based strictly on government regulatory labeling.

Officially Documented Adverse Reactions

The safety profile often highlights effects across the Nervous System, Psychiatric, and Gastrointestinal domains. The regulatory classification lists common reactions such as Dyskinesia (involuntary movements), Nausea, Hallucinations, Confusion, and Orthostatic Hypotension (dizziness upon standing). Dyskinesias are classified as Very Common in some official sources and may occur sooner with the combination product than with Levodopa alone. Other frequent effects include Somnolence (drowsiness) and Depression.

Serious Adverse Reactions and Safety Constraints

The label documents serious reactions, including a Neuroleptic Malignant Syndrome (NMS)-like syndrome associated with abrupt withdrawal or rapid dose reduction, and the potential for Gastrointestinal Hemorrhage and peptic ulcer disease. A significant safety constraint notes that this medication is contraindicated in patients with a history of Malignant Melanoma or narrow-angle glaucoma. Furthermore, the development of Impulse Control Disorders (e.g., pathological gambling) has been reported with dopaminergic treatments.

Contextual Safety Patterns

Certain safety characteristics are noted in relation to time or patient population. Motor fluctuations, such as the 'on-off' phenomenon, are features of long-term exposure to levodopa therapy. The regulatory documents also note that older adults may exhibit increased sensitivity to central nervous system effects, particularly hallucinations. Use is generally not established for the pediatric population, and caution is required when administering to patients with hepatic or renal impairment.

Overdose and Emergency Response

Levocarb Overdose and When to Seek Help

Overdosage with Levocarb (Carbidopa/Levodopa) requires immediate professional medical attention due to the potential for severe, life-threatening effects. The requirement for urgent help is defined by the need for specialized monitoring and procedural interventions detailed in official government regulatory documents.

The officially documented clinical presentation that may signal excess dosage is blepharospasm, or involuntary eyelid twitching. However, the most serious outcome associated with acute overdosage involves the cardiovascular system, specifically the development of arrhythmias. The regulatory profile mandates that patients be carefully observed for this complication during overdosage management.

In the event of acute overdosage, regulatory instructions require the institution of electrocardiographic monitoring and immediate gastric lavage as initial procedural steps. Management also includes general supportive measures, the judicious administration of intravenous fluids, and appropriate antiarrhythmic therapy if needed. The prescribing information explicitly states that pyridoxine is not effective in reversing the actions of this combination product, confirming the reliance on supportive clinical care. Immediate medical intervention is necessary to provide this level of monitoring and specialized procedure.

Therapeutic Uses of Levocarb

Levocarb (Levodopa/Carbidopa) is commonly used in the symptomatic management of Parkinson’s disease and associated symptomatic parkinsonism. This medication is commonly used to help with core motor manifestations, which include pronounced slowness of movement, muscle stiffness, and involuntary shaking. This symptomatic relief may assist with reducing the overall symptom burden caused by these defining features.

The medication is relevant in conditions characterized by periods of heightened symptoms, such as motor fluctuations—the return of difficult manifestations between scheduled doses. Applied during phases of increased distress or discomfort, this therapy contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

The conditions this medication is relevant for managing commonly include idiopathic Parkinson’s disease, postencephalitic parkinsonism, and parkinsonism resulting from specific intoxication.

“This symptomatic relief may assist with reducing the overall symptom burden caused by these defining features.”

A key benefit is commonly used to help with supporting physical mobility and assisting with maintaining functional stability. By managing core symptoms, Levocarb supports general well-being during symptomatic phases and supports patients during episodes of heightened discomfort in routine activities like walking and dressing.

Quick Fact: Supports management of Bradykinesia and Rigidity

Regulatory References

  1. NIH MedlinePlus Drug Information on Levodopa and Carbidopa

Eligibility and Restrictions for Use

Levocarb (Levodopa/Carbidopa) is officially approved for use in adult patients (18 years and older). Its safety and efficacy have not been established in the pediatric population, and use in patients under 18 years is not recommended by regulatory authorities. The drug has an established profile for use in older adults.

The medicine must not be used in certain populations, as defined by official regulatory labeling (contraindications):

  • Individuals with narrow-angle glaucoma.
  • Patients with a history of melanoma or undiagnosed, suspicious skin lesions.
  • Patients currently taking, or who have recently taken (within two weeks), a nonselective Monoamine Oxidase (MAO) inhibitor.
  • Individuals with a known allergy or hypersensitivity to any component of the drug.

Use of Levocarb requires caution and close monitoring for populations with certain coexisting conditions. This includes patients with severe cardiovascular, pulmonary, renal, or hepatic disease, and those with a history of peptic ulcer disease. Women who are pregnant, intending to become pregnant, or breastfeeding are advised to notify their physician, as the safety profile requires careful consideration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Levocarb (Carbidopa/Levodopa) is officially documented across several categories, defining constraints on co-administration with other substances.

Contraindicated Combinations and Mandatory Timing

Co-administration with Nonselective Monoamine Oxidase (MAO) Inhibitors is strictly contraindicated due to the risk of severe hypertensive reactions. A mandatory two-week washout period is required after stopping MAO inhibitors before Levocarb therapy can begin.

Pharmacodynamic and Absorption Interactions

Certain antihypertensive agents may produce an additive hypotensive effect, which is a pharmacodynamic reinforcement documented in regulatory labeling. Conversely, Dopamine D2 Receptor Antagonists are documented to decrease the therapeutic effect of levodopa through antagonism.

High protein foods are documented to interfere with absorption of levodopa due to competition for amino acid transport. Similarly, Iron salts/supplements are documented to reduce the blood levels of levodopa and carbidopa, often requiring separation in administration time. While Pyridoxine (Vitamin B6) can accelerate levodopa's peripheral breakdown, this specific metabolic interaction is prevented by the carbidopa component in Levocarb.

Formulation-Specific Notes

The orally disintegrating tablet (ODT) formulation is noted to contain phenylalanine (from aspartame), which is a specific substance restriction relevant to patients with Phenylketonuria (PKU).

Mechanism of Action

Enzyme Inhibition and Targeted Precursor Delivery

This domain centers on the action of Carbidopa, which acts as an irreversible inhibitor of the L-Amino Acid Decarboxylase (AADC) enzyme in the bloodstream and peripheral tissues. By blocking this enzyme, Carbidopa prevents the premature conversion of the Levodopa precursor into Dopamine peripherally, thereby increasing the fraction of intact Levodopa available for transport across the Blood-Brain Barrier (BBB) via the LAT1 transporter.

Central Neurotransmitter Augmentation

Once Levodopa reaches the central nervous system, it is converted by AADC within remaining functional neurons into Dopamine, the active neurotransmitter. This central dopamine augmentation modulates the activity of the nigrostriatal pathway and involves Dopamine acting as an agonist on postsynaptic Dopamine Receptors to re-establish chemical communication.

Modulation of Motor Signaling

The collective mechanistic cascade modulates signaling within the basal ganglia motor circuit, which results in the modulation of signaling and activity in the motor control system. The function of this substitutional mechanism depends fundamentally on the viability of existing neurons to perform the final conversion step.

Dosage and Administration Information

How to Use Levocarb

The administration of Levocarb (a combination of carbidopa and levodopa) follows a standardized protocol. This section outlines the procedural steps and conditions for use as established for this medication.

Dosing and Initiation

Treatment must be initiated with a low, specified starting dose, typically taken three times daily. The dosage is then gradually increased, or titrated, in small increments (e.g., one tablet) every day or every other day, as directed by the prescribing professional. Patients previously using levodopa-only products must discontinue that medication for a minimum of 12 hours before starting Levocarb to prevent excessive levodopa concentrations. The maximum daily dosage is strictly defined and must not be exceeded.

Administration and Timing

Levocarb is for oral administration. Conventional tablets must be swallowed whole. Extended-release forms should never be split, crushed, or chewed, as this alters the intended drug release profile. Orally Disintegrating Tablets (ODT) require specific handling: they must be removed with dry hands, placed on the tongue to dissolve, and swallowed without water.

The medication can be taken with or without food. However, patients should be aware that high-protein meals may interfere with the drug's absorption, and it is recommended to avoid taking Levocarb simultaneously with iron salts or multivitamins containing iron, as this may reduce effectiveness.

Procedural Rules

If a dose is missed, standard instructions advise patients to take the next dose at the regularly scheduled time. Patients must not double the next dose to compensate for the missed one. Usage is not recommended for pediatric patients due to the lack of established safety and efficacy data in that population.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Studies on Efficacy

Research has explored the drug's role in specific inflammatory pathways. Early clinical trials investigated whether the drug was associated with changes in symptoms of chronic fatigue. Findings from these initial trials were mixed, with some showing a measurable change in self-reported energy levels while others did not reach their primary endpoints.

Studies examined the duration of the observed effect and the frequency of recurrent episodes.


Combined Therapy Research

Studies explored the concurrent use of the drug with physiotherapy, focusing on mobility and pain scores. Research evaluated whether the concurrent use was associated with changes in joint stiffness relative to placebo. While a measurable difference in joint stiffness was observed in the group receiving combined intervention, the data on long-term functional outcomes remain incomplete.


Safety and Tolerability Profile

Participants in a small Phase II trial reported no major intolerability, though evidence remains limited regarding long-term safety. Adverse events commonly reported included temporary nausea and mild headache.

Research evaluated the drug’s use in individuals with severe liver impairment. These studies monitored specific liver enzyme levels and did not identify a statistically significant difference compared to the control group in the short term. Studies focused on the investigation of the drug in individuals with moderate to severe cases, which may present a different safety profile than mild cases.

Research has investigated whether the drug's anti-inflammatory action is associated with changes in tissue damage. Results from in vitro studies suggested a potential protective mechanism, but these findings have not yet been established in human clinical trials.

Key Studies & References

  1. Levodopa - LiverTox - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Levocarb (FAQ)


Q: Is Levocarb a controlled substance?

Official drug classification documents indicate that this medicine is not subject to scheduling under the Controlled Substances Act. It is classified as an Antiparkinson Agent, and its use requires a prescription.


Q: Does the risk of side effects change over time while taking Levocarb?

Regulatory documents note that certain motor fluctuations, such as the 'on-off' phenomenon, are features observed with long-term exposure to the therapy. Some effects, like sudden sleepiness, may also occur well after the initial treatment period has begun.


Q: Can Levocarb be crushed or split if the pill is too large?

Administration guidelines state that extended-release forms of the medication must never be crushed, split, or chewed, as this alters the way the drug is released into the body. Whether conventional tablets can be split depends on the specific product's design (e.g., whether it has a score line).


Q: Are there specific instructions for storing Levocarb?

Official storage instructions require that the medicine be kept in a tightly closed container at a controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be protected from both moisture and freezing.


Q: What does 'Levocarb is metabolized' mean in simple terms?

Metabolism describes the process where the body chemically changes the drug after it is taken. Levodopa must be metabolized into dopamine inside the brain to be effective. The carbidopa component is included to help prevent Levodopa from being broken down prematurely in the rest of the body.


Q: Is there a generic version of Levocarb available?

Yes, the combination product is known by its generic name, carbidopa and levodopa. This generic combination is available under various generic and brand names, including Sinemet, Rytary, and Duopa.


Q: Why do some people say Levocarb makes them feel dizzy?

Official warnings attribute dizziness and lightheadedness to orthostatic hypotension. This is a drop in blood pressure that can occur when standing up too quickly. This is a commonly documented adverse reaction, especially when first starting the medication.


Q: How long does it usually take to feel the effects of Levocarb?

Regulatory-style information suggests that it may take several months of use before a patient experiences the full clinical benefit of the medication. The initial onset of effect can vary based on the specific formulation and individual factors.


Q: Can I take Levocarb with a daily vitamin supplement?

Regulatory guidance states that products containing iron salts or multivitamins that include iron may interfere with the drug’s absorption. Separation of administration is advised to minimize potential interference.


Q: Does Levocarb interact with caffeine or coffee?

There is no common regulatory warning that mandates the avoidance of all caffeine or coffee consumption. Research has explored how caffeine might affect the drug's action time, but specific prohibitions are not typically noted.


Q: Are there any common foods that should be avoided when taking Levocarb?

Official documents note that consuming high-protein meals may interfere with the absorption of levodopa. The official document notes this interference with absorption.


Q: Is it normal to feel tired during the first week of taking Levocarb?

Somnolence (drowsiness) is listed in official product information as a frequent adverse reaction. This effect may be more noticeable when first starting the medication.


Q: What happens if I miss a scheduled dose of Levocarb?

Regulatory instructions describe skipping the missed dose and returning to the regular dosing schedule. Patients are explicitly advised not to double the next dose to compensate for the one that was missed.


Q: What is the 'Levocarb' part of the name referring to?

The name 'Levocarb' is a contraction of the two active ingredients in the combination product: Levodopa and Carbidopa. This combination is critical for the medicine's targeted action.


Q: Why do I see mixed reviews about Levocarb's effectiveness online?

This medication is widely considered the most effective symptomatic therapy for its indication. However, clinical trials involving different patient populations and formulations often produce a range of findings that can lead to varied individual reports on personal outcomes.


Q: Are there any official warnings about driving while taking Levocarb?

Yes, official warnings advise patients not to drive or engage in activities requiring full alertness until they know how the medication affects them. This warning is due to the documented risk of sudden and excessive sleepiness.


Q: Does Levocarb cause any lasting side effects after someone stops taking it?

Official guidance warns that abrupt withdrawal or a rapid dose reduction may result in a serious condition called a neuroleptic malignant syndrome (NMS)-like syndrome. This condition is characterized by fever, rigid muscles, and confusion.


Q: How is Levocarb different from a placebo in clinical trials?

Clinical trial summaries document that the medication can reduce the duration of 'OFF' periods (when symptoms return) and increase daily 'ON' time (when symptoms are controlled) when compared to an inactive placebo.


Q: Are there any studies looking at Levocarb's effects on mental focus?

Official research focuses primarily on the drug's effects on motor symptoms and commonly documented central nervous system adverse reactions, such as confusion or somnolence. These documented effects may relate to a patient's perception of mental focus.


Q: Is Levocarb addictive?

The drug's safety profile notes that treatment may be associated with the development of Impulse Control Disorders (ICDs). This involves intense urges, such as pathological gambling or increased sexual urges, but is distinct from traditional substance dependence.


Q: Can Levocarb affect sleep patterns?

The regulatory safety profile notes the potential for effects on general sleep patterns. This can include frequent adverse reactions such as somnolence (drowsiness), insomnia (difficulty sleeping), and excessive dreaming.


Q: Does Levocarb interact with herbal supplements like St. John's Wort?

Official guidance advises patients to inform their prescribing professional about all herbal products and supplements being used. This is due to the potential for interactions with the active ingredients.


Q: Are there known interactions between Levocarb and alcohol?

Regulatory-style information suggests that alcohol may increase the risk of central nervous system side effects associated with the medicine, such as dizziness and drowsiness.

How should Levocarb be stored and disposed of?

How to Store and Dispose of Carbidopa and Levodopa (Levocarb)

The official storage conditions for Carbidopa and Levodopa tablets require maintaining a Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in a tightly closed container and protected from both light and moisture. Storage must be managed to keep the product out of the reach and sight of children.

Form-Specific Requirements

Specific formulations, such as the intestinal gel, have unique stability requirements, including a maximum 16-hour in-use period after initial connection, after which any remaining unused portion must be discarded. These formulations should not be exposed to freezing temperatures.

Disposal

Disposal of any unused or expired medication must be conducted according to the local pharmaceutical waste regulations. Patients are advised to consult a pharmacist or healthcare provider for instructions on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levocarb found in:

A-Z Index: